Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PERCIST Evaluation of Trastuzumab Deruxtecan in the Treatment of HER2 Low Breast Cancer

NCT07130344 is registered in ClinicalTrials.gov with Centre Paul Strauss as lead sponsor.

NCT NCT07130344
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07130344 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PERCIST Evaluation of Trastuzumab Deruxtecan in the Treatment of HER2 Low Breast Cancer
Lead sponsor
Centre Paul Strauss
Phase
Not applicable
Overall status
Not yet recruiting
Start date
September 30, 2025
Completion date
September 30, 2030
Enrollment
262 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her 2 low-expressing breast cancer, metastatic breast cancer